These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 23462052)
1. Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia. Vos JM; Minnema MC; Wijermans PW; Croockewit S; Chamuleau ME; Pals ST; Klein SK; Delforge M; van Imhoff GW; Kersten MJ; ; Neth J Med; 2013 Mar; 71(2):54-62. PubMed ID: 23462052 [TBL] [Abstract][Full Text] [Related]
2. A survey on diagnostic methods and treatment strategies used in patients with Waldenström's macroglobulinaemia in The Netherlands. Klodzinska S; Vos JM; Kersten MJ; Wijermans P; Minnema MC Neth J Med; 2013 Mar; 71(2):90-6. PubMed ID: 23462060 [TBL] [Abstract][Full Text] [Related]
3. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120 [TBL] [Abstract][Full Text] [Related]
4. [Pathology, diagnostics, and treatment of Waldenström's macroglobulinaemia]. Holmström MO Ugeskr Laeger; 2011 Oct; 173(41):2557-60. PubMed ID: 21985832 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118 [TBL] [Abstract][Full Text] [Related]
6. Blurry Vision as a Presentation of Waldenström's Macroglobulinemia: A Case Report With Review of Current Management. Adams TN; Jetly-Shridhar R; Tran D; Boulmay BC J Investig Med High Impact Case Rep; 2022; 10():23247096211052187. PubMed ID: 35258381 [TBL] [Abstract][Full Text] [Related]
9. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119 [TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910 [TBL] [Abstract][Full Text] [Related]
15. [Waldenström's macroglobulinemia: clinical aspects, diagnosis and therapy]. Baldus M; Brass H Med Klin (Munich); 1992 Aug; 87(8):434-6. PubMed ID: 1406477 [No Abstract] [Full Text] [Related]
16. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia. Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974 [TBL] [Abstract][Full Text] [Related]